Abstract
17048 Background: This is a feasibility/phase II trial with GC on a 21-day cycle, with G and C split between d1, 8. Split dose C allowed administration in an outpatient setting. Objectives: To document the toxicity and define the objective response rate; and determine progression free and overall survival. Methods: Pts with stage III/IV NSCLC received: G/C 1250/40mg/m2 (G and C given on d1, 8 every 3 wks). Eligibility: ECOG PS 0–2, adequate bone marrow/liver function, calculated GFR > 50 ml/min. Results: 56 pts enrolled, all evaluable for toxicity; 47 evaluable for response; 4 patients too early for response assessment and 5 patients did not complete 1 cycle of chemotherapy. Characteristics: 70% male, median age 66 yrs (41–77), 25% GFR 50- 60 ml/min, 62% Stage IV. Radiotherapy was allowed after completing chemotherapy. 165 cycles have been delivered. Cycles with hematological toxicity: Grade 3: 5 anaemia, 17 neutropenia, 6 thrombocytopenia; Grade 4: 7 neutropenia, 4 thrombocytopenia. There were 3 episodes...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
